Viking Therapeutics Inc (VKTX) Expected to Post Earnings of -$0.11 Per Share

Brokerages predict that Viking Therapeutics Inc (NASDAQ:VKTX) will post ($0.11) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Viking Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Viking Therapeutics posted earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year over year growth rate of 21.4%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, March 6th.

On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.44) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.41). For the next year, analysts forecast that the company will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.55) to ($0.39). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.01.

Several analysts have recently weighed in on the stock. SunTrust Banks assumed coverage on shares of Viking Therapeutics in a report on Friday, July 20th. They set a “buy” rating and a $14.00 price objective for the company. Roth Capital raised their price objective on shares of Viking Therapeutics from $13.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, September 19th. Maxim Group reaffirmed a “buy” rating and set a $28.00 price objective on shares of Viking Therapeutics in a report on Thursday. BidaskClub lowered shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 3rd. Finally, Raymond James set a $43.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a report on Wednesday, September 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Viking Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $28.17.

In related news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total value of $5,034,171.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.90% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. American International Group Inc. increased its holdings in shares of Viking Therapeutics by 21.3% in the third quarter. American International Group Inc. now owns 34,403 shares of the biotechnology company’s stock valued at $599,000 after purchasing an additional 6,036 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Viking Therapeutics by 12.0% in the third quarter. Wells Fargo & Company MN now owns 65,810 shares of the biotechnology company’s stock valued at $1,146,000 after acquiring an additional 7,037 shares during the last quarter. First Mercantile Trust Co. bought a new position in Viking Therapeutics in the third quarter valued at approximately $131,000. Janney Montgomery Scott LLC bought a new position in Viking Therapeutics in the second quarter valued at approximately $114,000. Finally, Strs Ohio bought a new position in Viking Therapeutics in the second quarter valued at approximately $120,000. 53.56% of the stock is owned by institutional investors and hedge funds.

NASDAQ VKTX opened at $12.33 on Wednesday. The company has a market cap of $833.44 million, a PE ratio of -15.61 and a beta of 2.92. Viking Therapeutics has a 1-year low of $2.24 and a 1-year high of $24.00.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Read More: How is inflation measured?

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply